193 related articles for article (PubMed ID: 11456213)
1. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
Herings RM; Klungel OH
Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
[TBL] [Abstract][Full Text] [Related]
2. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
[TBL] [Abstract][Full Text] [Related]
4. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of interventions by community pharmacists to reduce risk of gastrointestinal side effects in nonselective nonsteroidal anti-inflammatory drug users.
Teichert M; Griens F; Buijs E; Wensing M; De Smet PA
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):382-9. PubMed ID: 24535837
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.
Laine L; Wogen J; Yu H
Gastroenterology; 2003 Aug; 125(2):389-95. PubMed ID: 12891540
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
[TBL] [Abstract][Full Text] [Related]
10. The iatrogenic costs of NSAID therapy: a population study.
Sturkenboom MC; Romano F; Simon G; Correa-Leite ML; Villa M; Nicolosi A; Borgnolo G; Bianchi-Porro G; Mannino S
Arthritis Rheum; 2002 Apr; 47(2):132-40. PubMed ID: 11954006
[TBL] [Abstract][Full Text] [Related]
11. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
12. [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects].
Lanas A
Med Clin (Barc); 2000; 114 Suppl 3():46-53. PubMed ID: 10994564
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study
.
Han MH; Nam JH; Noh E; Lee EK
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273
[TBL] [Abstract][Full Text] [Related]
15. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies.
Pilotto A; Franceschi M; Leandro G; Di Mario F;
Drugs Aging; 2003; 20(9):701-10. PubMed ID: 12831293
[TBL] [Abstract][Full Text] [Related]
16. The economic consequences of NSAID-induced gastrointestinal damage.
de Pouvourville G; Tasch RF
Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
[TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan.
Chang CH; Lin JW; Chen HC; Kuo CW; Shau WY; Lai MS
Gut; 2011 Oct; 60(10):1372-8. PubMed ID: 21415083
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study.
Knijff-Dutmer EA; Postma MJ; van der Palen J; Brouwers JR; van de Laar MA
Clin Ther; 2004 Jul; 26(7):1160-7. PubMed ID: 15336481
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K; Fastbom J
Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
